Illumina’s second quarter performance in 2025 was met with a significant negative market reaction, as shares declined in response to ongoing revenue contraction and sharply lower operating margins. Management attributed the sales decline primarily to continued weakness in the U.S. research funding environment, where academic and government customers delayed projects due to uncertainty around National Institutes of Health (NIH) grants. CEO Jacob Thaysen highlighted that “the research environment, particularly in the U.S., remains constrained,” and confirmed that while clinical segment demand proved resilient, softness in research spending weighed on overall results.
Genomics company Illumina (NASDAQ:ILMN) reported Q2 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 3% year on year to $1.06 billion. Its non-GAAP profit of $1.19 per share was 17.7% above analysts’ consensus estimates.
Illumina will pay $9.8 million to settle allegations it sold genomic systems with cybersecurity flaws to U.S. agencies. A whistleblower will receive $1.9 million.
Shares of genomics company Illumina (NASDAQ:ILMN) fell 6.1% in the afternoon session as investors reacted to its second-quarter earnings report, where a year-over-year revenue decline overshadowed beats on profit and sales forecasts. The life sciences company reported that revenue fell 3% from the prior year, sparking concerns about its growth trajectory. Management pointed to challenges in the research market, citing uncertainty around National Institutes of Health (NIH) funding and ongoing export restrictions that limited sales in China. These company-specific issues were compounded by broader market fears over new tariffs and weak U.S. jobs data. While Illumina did raise its full-year profit guidance and announced the acquisition of SomaLogic, investors focused on the top-line revenue weakness.
Genomics company Illumina (NASDAQ:ILMN) beat Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 3% year on year to $1.06 billion. Its non-GAAP profit of $0.36 per share was 64.4% below analysts’ consensus estimates.
Shares of genomics company Illumina (NASDAQ:ILMN) jumped 3.7% in the pre-market session after analysts at Robert W. Baird increased their price target on the life sciences company's stock to $105.00. While the firm maintained its 'neutral' rating on the shares, the new price objective represented a significant increase from the previous target of $84.00. This analyst action followed Illumina's recent quarterly report, where the company posted earnings and revenue that narrowly beat Wall Street's consensus estimates. The life sciences company reported earnings per share of $0.97 and revenue of $1.04 billion. This performance, coupled with the revised price target, appeared to have bolstered investor confidence.
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages.
Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Shares of genomics company Illumina (NASDAQ:ILMN) fell 4.2% in the morning session after a Citi analyst downgraded the stock to 'Sell' from 'Neutral' and lowered the price target.
Shares of genomics company Illumina (NASDAQ:ILMN) fell 3.6% in the afternoon session after the major indices pulled back (Nasdaq -0.8%, S&P 500 -0.77%), largely due to escalating concerns surrounding the July 9th deadline for new US tariffs, now amplified by specific announcements.
Illumina’s first quarter results reflected ongoing challenges in the global genomics market, as the company’s performance fell short of market expectations, prompting a negative reaction from investors. Management attributed recent revenue declines to a combination of restricted instrument exports to China, a constrained research funding environment in the U.S., and evolving trade dynamics. CEO Jacob Thaysen acknowledged these headwinds, emphasizing, "Developments around China, U.S. funding uncertainty, and global trade dynamics have introduced new pressures for our customers." Despite these pressures, Illumina highlighted continued strength in clinical markets and ongoing adoption of its NovaSeq X platform.
